Literature DB >> 25146084

The association between blood lipid and phlegm turbidity syndrome of angina pectoris: a systematic review and meta-analysis.

Dezhao Kong1, Yang Wang1, Yue Liu1, Zhe Zhang1, Guanghui Liu1, Wencheng Qi1, Lei Xiao1, Dongchao Yuan2, Guanlin Yang3.   

Abstract

BACKGROUND: A series of case-control studies have been conducted to investigate the association between blood lipid and phlegm turbidity syndrome of angina pectoris, but produced inconsistent results.
OBJECTIVE: We performed a meta-analysis to determine the association between blood lipid and phlegm turbidity syndrome of angina pectoris more precisely.
METHODS: Manual screening as well as screening of the China National Knowledge Infrastructure (CNKI), Chinese Journal full-text database (VIP), Wanfang database (WF), ScienceDirect, Pubmed, the Cochrane Library, and Embase were carried out for relevant literature. The formula was translated to calculate the pooled mean value and standard deviation value. The "Newcastle-Ottawa Quality Assessment Scale: Case-Control Studies" (NOS) was taken to assess the quality of the included studies. The Revman 5.2.6 software provided by "The Cochrane Collaboration" was used to analyze the collected data. The subgroup analysis was established according to the sample size proportion between the test group and the control group. Sensitivity analysis was constructed by using two different effect models. Besides, a funnel plot was created to analyze potential publication bias.
RESULTS: No statistically meaningful difference existed between the test group and control group of total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) in non-Qi and yin deficiency syndrome (QYDS) and non-Yang deficiency syndrome (YDS) subgroup, whereas the two biotic indicators in the test group were higher than the non-phlegm syndrome group in other subgroups. Triglyceride (TG) in phlegm syndrome group showed superior to non-phlegm syndrome group in the rest subgroups except for the non-CCS (Cold coagulating syndrome)-non-YDS subgroup. High-density lipoprotein-cholesterol (HDL-C) levels of the phlegm group were lower than that of the non-phlegm group in all subgroups.
CONCLUSION: When comparing with Traditional Chinese Medicine (TCM) syndromes of asthenia nature, such as YDS, QYDS, and heart qi deficiency syndrome), the levels of TG, TC, and LDL-C were higher in phlegm turbidity syndrome. However, for sthenia syndromes such as Qi stagnation syndrome (QSS), heart blood stasis syndrome (HBSS), and CCS, there was no obvious difference. Furthermore, HDL-C levels in the phlegm turbidity group were lower than those of the non-phlegm group. Nevertheless, these results should be confirmed with further studies.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Angina pectoris; Blood lipid; Meta-analysis; Phlegm turbidity syndrome

Mesh:

Substances:

Year:  2014        PMID: 25146084     DOI: 10.1016/j.ctim.2014.05.008

Source DB:  PubMed          Journal:  Complement Ther Med        ISSN: 0965-2299            Impact factor:   2.446


  4 in total

1.  Sublingual Nodules: Diagnostic Markers of Metastatic Breast Cancer.

Authors:  Xue Yang; Cui-Hong Zhu; Rui Cao; Jian Hao; Xiong-Zhi Wu
Journal:  Chin J Integr Med       Date:  2018-04-17       Impact factor: 1.978

2.  Integrated Modules Analysis to Explore the Molecular Mechanisms of Phlegm-Stasis Cementation Syndrome with Ischemic Heart Disease.

Authors:  Wei-Ming Xu; Kuo Yang; Li-Jie Jiang; Jing-Qing Hu; Xue-Zhong Zhou
Journal:  Front Physiol       Date:  2018-01-22       Impact factor: 4.566

Review 3.  The Effect of Chinese Herbal Medicine Gualouxiebaibanxia Decoction for the Treatment of Angina Pectoris: A Systematic Review.

Authors:  Wei Liu; Xingjiang Xiong; Xiaochen Yang; Fuyong Chu; Hongxu Liu
Journal:  Evid Based Complement Alternat Med       Date:  2016-09-29       Impact factor: 2.629

4.  A Real-World Evidence Study for Distribution of Traditional Chinese Medicine Syndrome and Its Elements on Respiratory Disease.

Authors:  Fei Xu; Wengqiang Cui; Qing Kong; Zihui Tang; Jingcheng Dong
Journal:  Evid Based Complement Alternat Med       Date:  2018-12-12       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.